Headlines Specialties Covid-19 Trending Feeds ASCO20 Videos

OncLive - Interim data from a phase 2 study indicate that neoadjuvant hormone therapy may reduce tumor volume in men with high-risk prostate cancer planning to...

Targeted Oncology - Hagen F. Kennecke, MD, MHA, FRCP, medical oncologist, medical director of the Virginia Mason Cancer Institute and current chair of the NCI Rectal-Anal Cancer...

OncLive - David H. Ilson, MD, PhD, discusses the utility of zolbetuximab in claudin-positive gastric...

Oncology Nursing News - Patients with metastatic HER2-positive breast cancer who later develop central nervous system (CNS) metastases comprise a large population of all patients with breast cancer,...

  • There continues to be an unmet need for patients with metastatic HER2-positive breast cancer who later develop central nervous system metastases, though these individuals comprise a large population of all patients with breast cancer. https://t.co/vymxZVN5tl

OncLive - Shubham Pant, MD, discusses key data that emerged in the gastrointestinal oncology space from the 2020 ASCO Virtual Scientific...

JAMA Network - In this issue of JAMA Oncology, Diefenhardt and colleagues1 report a post hoc analysis of the previously published German CAO/ARO/AIO-04 trial2 and found that...

  • Invited commentary highlights new data on adherence to neoadjuvant chemoradiation for rectal cancer & outcome, raising question of whether this association represents correlation or causation when assessing retrospective data https://t.co/S1qseHGTWm #GICSM #CRCSM

Targeted Oncology - Based on phase 3 findings, F-627 appears at least as efficacious and safe as pegfilgrastim, which is the current standard of care, demonstrating strong...

OncLive - Dimitrios Tzachanis, MD, PhD, discusses research regarding post–CAR T-cell therapy progression in...

OncLive - The European Commission has approved single-agent olaparib as a maintenance treatment for adult patients with germline BRCA1/2-mutant metastatic pancreatic adenocarcinoma who have not progressed...